Business
Use of Parsortix in head and neck cancer
Use of Parsortix in head and neck cancer.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 2040M Angle PLC 13 September 2019 \n\n \n\n\n\n\nFor immediate release\n\n\n13 September 2019\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nPUBLICATION ON USE OF PARSORTIX IN HEAD AND NECK CANCER \n \n Opportunity for Parsortix to be used for PD-L1 analysis of CTCs to assess whether patients will benefit from immunotherapies \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University of Birmingham has published results of a review of research into the use of circulating tumor cell (CTC) markers in the treatment of head and neck cancer identifying some key benefits of ANGLE's Parsortix® system over other CTC liquid biopsy systems.\n \nThe review has been published as a peer-reviewed publication in the journal Cancers and is available at https://angleplc.com/library/publications/. \n \nThe review identifies key potential uses of a CTC liquid biopsy to:\n· facilitate accurate patient risk stratification\n· guide treatment selection\n· predict response and identify the failure of treatment early, allowing a timely shift of therapeutic strategy.\n \nKey advantages, over traditional tissue biopsies, include the ability to repeat the investigation at multiple time points and a reduction in overall healthcare costs.\n \nIdentified advantages of the Parsortix system, over other CTC liquid biopsy systems, are that it is not antibody-dependent and is able to detect all sub-populations of CTCs as well as CTC clusters. Other liquid biopsy approaches have been shown to have significant limitations in this indication. \n \nA major opportunity identified by the review is the need to detect, through investigation of the harvested CTCs, whether the cancer is PD-L1 (programmed death-ligand 1) positive. PD-L1 is a potential biomarker for immunotherapy, which may indicate likely response to immunotherapy drugs. ANGLE is developing its processes for investigation of CTCs to determine the presence or absence of PD-L1 expression and this work is already well advanced.\n \nHead and neck cancer is the sixth most common cancer worldwide with some 650,000 new patients diagnosed annually resulting in more than 350,000 deaths...